Assurex Health

Medtech · Private

Pharmacogenomic testing service that analyzes genetic variants to guide psychiatric medication selection

assurexhealth.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
$171K
5 awards · Veterans Affairs, Defense
#471 of 4531 in medtech
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Veterans Affairs · :igf::ot::igf: Genesightrx Psychotropic Test$28,283
Federal contractDepartment of Veterans Affairs · Gene Testing ''igf::ot::igf''$26,515
Federal contractDepartment of Veterans Affairs · Igf::ot::igf Genesightrx Psychotropic Test$70,707
Federal contractDepartment of Defense · Pharmacogenetic Lab Testing$20,400
Federal contractDepartment of Defense · Pharmacogenetic Lab Testing$25,200
Federal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
468ISCIENCE INTERVENTIONAL CORP$174K$24M
469EVREN TECHNOLOGIES, INC.$172K—
470SPARK BIOMEDICAL INC.$171K$16M
471Assurex Health$171K—
472Gold Standard Diagnostics Corp.$167K$2.5M
473CMP Scientific Corp$167K$300K
474IONICSCALE LLC$166K—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Methods For Treating Opioid Addictionapplication
  • Compositions And Methods Relating To Identification Of Genetic Variantsapplication
  • Compositions And Methods Relating To Identification Of Genetic Variantsapplication
  • Methods For Treating Opioid Addictionapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.